VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer

VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer

Bibliográfalaš dieđut
Váldodahkkit:	Redchenko, I, Cappuccini, F, Pollock, E, Bryant, R, Carter, L, Verrill, C, Hollidge, J, Goodwin, L, Harrop, R, Romero, P, Vigano, S, Evans, T, Catto, J, Hamdy, F, Hill, A
Materiálatiipa:	Conference item
Almmustuhtton:	American Society of Clinical Oncology 2018

Geahča maid

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
Dahkki: Wajja, A, et al.
Almmustuhtton: (2024)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
Dahkki: Zhang, C, et al.
Almmustuhtton: (2023)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
Dahkki: Charlotte Davis, et al.
Almmustuhtton: (2024-06-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
Dahkki: Cheng Zhang, et al.
Almmustuhtton: (2023-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
Dahkki: Adam Berg, et al.
Almmustuhtton: (2021-10-01)

Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses
Dahkki: Alex Olvera, et al.
Almmustuhtton: (2024-03-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
Dahkki: Hermosilla, E, et al.
Almmustuhtton: (2022)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
Dahkki: Ogbe, A, et al.
Almmustuhtton: (2022)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
Dahkki: Alharbi, N, et al.
Almmustuhtton: (2017)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
Dahkki: Eduardo Hermosilla, et al.
Almmustuhtton: (2022-03-01)

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: A phase I clinical trial
Dahkki: Cappuccini, F, et al.
Almmustuhtton: (2020)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Dahkki: Ane Ogbe, et al.
Almmustuhtton: (2022-04-01)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
Dahkki: Ashley C. Beavis, et al.
Almmustuhtton: (2023-07-01)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
Dahkki: Moreira Folegatti, P
Almmustuhtton: (2021)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
Dahkki: Bas de Laat, et al.
Almmustuhtton: (2022-07-01)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
Dahkki: Rujittika Mungmunpuntipantip, et al.
Almmustuhtton: (2021-11-01)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
Dahkki: Simone Barocci, et al.
Almmustuhtton: (2022-03-01)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
Dahkki: Giorgio Berlot, et al.
Almmustuhtton: (2022-01-01)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
Dahkki: Lea Krutzke, et al.
Almmustuhtton: (2022-07-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
Dahkki: Tamara Garibashvili, et al.
Almmustuhtton: (2022-06-01)

Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
Dahkki: Jennifer Serwanga, et al.
Almmustuhtton: (2024-01-01)

Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus
Dahkki: Sergio Utrilla-Trigo, et al.
Almmustuhtton: (2020-06-01)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
Dahkki: Wilkie, M, et al.
Almmustuhtton: (2019)

IgA Vasculitis Following ChAdOx1 nCoV-19 Vaccination
Dahkki: Manabendra Basu, et al.
Almmustuhtton: (2024-01-01)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
Dahkki: Gerardo Casucci, et al.
Almmustuhtton: (2021-06-01)

Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
Dahkki: Marek Mikołajczyk, et al.
Almmustuhtton: (2022-12-01)

Arterial thrombosis following first-dose ChAdOx1 vaccination: a case series
Dahkki: Christopher Ward, et al.
Almmustuhtton: (2022-05-01)

AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions
Dahkki: Md. Altamash Ahmad, et al.
Almmustuhtton: (2023-03-01)

ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐6
Dahkki: Loes H. Willems, et al.
Almmustuhtton: (2021-12-01)

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
Dahkki: Larissa Henze, et al.
Almmustuhtton: (2023-01-01)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
Dahkki: Salma Al Bahrani, et al.
Almmustuhtton: (2021-09-01)

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
Dahkki: Zoltán Bánki, et al.
Almmustuhtton: (2022-06-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Dahkki: Pedro M. Folegatti, et al.
Almmustuhtton: (2019-05-01)

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial
Dahkki: Andrew Protheroe, et al.
Almmustuhtton: (2020-05-01)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
Dahkki: Wang-Huei Sheng, et al.
Almmustuhtton: (2022-04-01)

Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
Dahkki: Stedman, A, et al.
Almmustuhtton: (2019)

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - author's reply
Dahkki: Voysey, M, et al.
Almmustuhtton: (2021)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Dahkki: Folegatti, P, et al.
Almmustuhtton: (2019)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
Dahkki: Edmund G.-T. Wee, et al.
Almmustuhtton: (2024-08-01)

Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
Dahkki: Leimapokpam Sumitra Devi, et al.
Almmustuhtton: (2022-01-01)